Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

被引：0
|
作者：
Yoshiaki Nakamura
Takeharu Yamanaka
Keisho Chin
Haruhiko Cho
Hitoshi Katai
Masanori Terashima
Kazunari Misawa
Motohiro Hirao
Kazuhiro Yoshida
Eiji Oki
Mitsuru Sasako
Yasunori Emi
Hideaki Bando
Yoshiyuki Kawashima
Tetsu Fukunaga
Masahiro Gotoh
Takako Ishibashi
Kohei Shitara
机构：
[1] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology
[2] Yokohama City University,Department of Biostatistics
[3] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastroenterology
[4] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[5] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Surgery
[6] National Cancer Center Hospital,Division of Gastric Surgery
[7] Shizuoka Cancer Center,Division of Gastric Surgery
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery
[9] National Hospital Organization Osaka National Hospital,Department of Surgery
[10] Gifu University,Department of Surgical Oncology, Graduate School of Medicine
[11] Kyushu University Hospital,Department of Surgery and Science, Graduate School of Medical Sciences
[12] Hyogo College of Medicine,Department of Surgery
[13] Saiseikai Fukuoka General Hospital,Department of Surgery
[14] Saitama Cancer Center,Department of Gastroenterological Surgery
[15] St. Marianna University School of Medicine,Department of Gastroenterological and General Surgery
[16] Osaka Medical College,Cancer Chemotherapy Center
[17] Yokohama City University Hospital,Center for Novel and Exploratory Clinical Trials
来源：
Annals of Surgical Oncology | 2019年 / 26卷
关键词：
Capecitabine Plus Oxaliplatin (CAPOX); Survival Outcomes; Gastric Cancer; pStage; Histological Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 472
页数：7
相关论文
共 50 条
  • [31] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
    Fujitani, Kazumasa
    Tamura, Shigeyuki
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    GASTRIC CANCER, 2014, 17 (02) : 348 - 353
  • [32] Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastrooesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
    Zhang, X.
    Li, Z.
    Liang, H.
    Xue, Y.
    Wang, Y.
    Zhou, Z.
    Yu, J.
    Chen, L.
    Du, Y.
    Li, G.
    Xiao, G.
    Wu, D.
    Zhou, Y.
    Dang, C.
    He, Y.
    Zhang, Z.
    Sun, Y.
    Li, Y.
    Shen, L.
    Ji, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1318 - S1319
  • [33] Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
    Yamada, Y.
    Higuchi, K.
    Nishikawa, K.
    Gotoh, M.
    Fuse, N.
    Sugimoto, N.
    Nishina, T.
    Amagai, K.
    Chin, K.
    Niwa, Y.
    Tsuji, A.
    Imamura, H.
    Tsuda, M.
    Yasui, H.
    Fujii, H.
    Yamaguchi, K.
    Yasui, H.
    Hironaka, S.
    Shimada, K.
    Miwa, H.
    Hamada, C.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 141 - 148
  • [34] Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy
    Tamura, Shigeyuki
    Fujitani, Kazumasa
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    ONCOLOGY, 2011, 80 (5-6) : 296 - 300
  • [35] Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
    Kang, Yoon-Koo
    Kim, Hyung-Don
    Cho, Hyungwoo
    Park, Young Soo
    Lee, Jong Seok
    Ryu, Min-Hee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [36] Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
    Wang, Guoxiu
    Zhao, Jiuda
    Song, Yan
    Zhang, Wen
    Sun, Yongkun
    Zhou, Aiping
    Huang, Jing
    Dui, Feng
    Yang, Lin
    BMC CANCER, 2018, 18
  • [37] Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
    Guoxiu Wang
    Jiuda Zhao
    Yan Song
    Wen Zhang
    Yongkun Sun
    Aiping Zhou
    Jing Huang
    Feng Du
    Lin Yang
    BMC Cancer, 18
  • [38] A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    YANG Lin
    SONG Yan
    ZHOU Ai-ping
    QIN Qiong
    CHI Yihebali
    HUANG Jing
    WANG Jin-wan
    中华医学杂志（英文版）, 2013, 126 (18) : 3470 - 3474
  • [39] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    LANCET, 2012, 379 (9813): : 315 - 321
  • [40] Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer
    Emi, Manabu
    Yamaguchi, Yoshiyuki
    Hihara, Jun
    Hironaka, Katsuji
    Okada, Morihito
    ONCOLOGY LETTERS, 2010, 1 (01) : 95 - 98
12345